Novartis receives EU approval for breast cancer drug Kisqali

ZURICH (Reuters) - Novartis AG said its drug Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer, bolstering the Swiss drugmaker's bid to challenge U.S. rival Pfizer's Ibrance.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news